
Home
Chapter Home
Jobs
Conferences
Fellowships
Books
Advertisement
Liver and intrahepatic bile ducts-nontumor
Metabolic diseases
Gaucher disease
Reviewers: Komal Arora, M.D. (see Reviewers page)
Revised: 25 April 2012, last major update April 2012
Copyright: (c) 2004-2012, PathologyOutlines.com, Inc.
General
=========================================================================
● Preferable to “Gaucher’s disease”
Etiology
=========================================================================
● Lysosomal storage disease caused by an autosomal recessive mutation in the β glucocerebrosidase gene (also called glucosylceramidase and β glucosidase)
● Defective enzyme leads to accumulation of glucocerebroside substrate in cells of the mononuclear phagocyte system, including histiocytes in the spleen, lymph nodes, bone marrow, GI and GU tracts; Kupffer cells in liver; osteoclasts in bone; microglia in CNS; and alveolar macrophages in lungs (Arch Pathol Lab Med 2008;132:851)
Epidemiology
=========================================================================
● Highest risk in Ashkenazi Jews - 1 in 15 are carriers
Clinical description
=========================================================================
● Three subtypes; all may have hepatosplenomegaly, hypersplenism, osteoporosis, yellow-brown skin, anemia (Gaucher Disease. GeneReviews™ [Internet] 1993-2000 Jul 27 [updated 2011 Jul 21])
● Type I - non-neuropathic, may be mild
● Type II (acute infantile neuropathic Gaucher disease) - affects infants within a few months of birth, usually fatal within 2 years; may have seizures and dementia
● Type III - chronic neurological variant, with onset anytime between birth and adulthood, presents with slowly progressing neurological decline; may have seizures and dementia
Diagnosis
=========================================================================
● <15% of mean normal glucocerebrosidase activity in peripheral blood leukocytes is diagnostic
● Note: enzyme activity in carriers (heterozygotes) is generally half-normal, but may overlap with healthy controls
● Molecular analysis, particular in Ashkenazi patients, may also be helpful
Case reports
=========================================================================
● 51 year old man with chronic liver disease (Case of the Week #164)
Treatment
=========================================================================
● Enzyme replacement therapy with imiglucerase (Cerezyme), a recombinant version of β glucocerebrosidase, for patients with Types I or III (Curr Opin Pediatr 2007;19:628)
Micro description
=========================================================================
● Enlarged Kupffer cells and portal macrophages with “crinkled paper” cytoplasm
Micro images
=========================================================================
Electron microscopy description
=========================================================================
● Intralysosomal tubular inclusions
● Angulated lysosomes
Electron microscopy images
=========================================================================
Thick section
Electron microscopy
Differential diagnosis
=========================================================================
● Niemann-Pick disease: foamy and vacuolated cytoplasm due to sphinomyelin accumulation
● Pompe disease: primarily affects skeletal and cardiac muscle
● Gaucher-like cells also seen in CML, AML and CLL
Additional references
=========================================================================
● eMedicine, Wikipedia, Am J Hematol 2011;86:110
End of Liver and intrahepatic bile ducts-nontumor > Metabolic diseases > Gaucher disease
This information is intended for physicians and related personnel, who understand that medical information is often imperfect, and must be interpreted in the context of a patient's clinical data using reasonable medical judgment. This website should not be used as a substitute for the advice of a licensed physician.
All information on this website is protected by copyright of PathologyOutlines.com, Inc. Information from third parties may also be protected by copyright. Please contact us at copyrightPathOut@gmail.com
with any questions (click here for other
contact information).